Galliprant

RSS

grapiprant

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Galliprant. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Galliprant.

For practical information about using Galliprant, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 17/08/2021

Authorisation details

Product details
Name
Galliprant
Agency product number
EMEA/V/C/004222
Active substance
grapiprant
International non-proprietary name (INN) or common name
grapiprant
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QM01AX92
Publication details
Marketing-authorisation holder
Elanco GmbH
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
09/01/2018
Contact address

Heinz-Lohmann-Str 4
27472 Cuxhaven
Germany

Product information

13/08/2021 Galliprant - EMEA/V/C/004222 - IB/0015

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other antiinflammatory and antirheumatic agents, non-steroids

Therapeutic indication

For the treatment of pain associated with mild to moderate osteoarthritis in dogs.

Assessment history

How useful was this page?

Add your rating
Average
4 ratings
1 rating